(Q29938766)

English

KIT T670I

genetic variant

T670I
THR670ILE
RS121913516

In more languages

default for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

human chromosome 4

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

55595519

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

55595519

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

negative therapeutic predictor for

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2924

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

determination method or standard

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4510

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

determination method or standard

CIViC evidence level D

CIViC 5-star trust rating

medical condition treated

gastrointestinal stromal tumor

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7416

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

determination method or standard

CIViC evidence level D

CIViC 5-star trust rating

medical condition treated

gastrointestinal stromal tumor

statement disputed by

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7417

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

determination method or standard

CIViC evidence level D

CIViC 5-star trust rating

medical condition treated

gastrointestinal stromal tumor

statement disputed by

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7417

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Identifiers

CIViC variant ID

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_000222.2:c.2009C>T

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

NP_000213.1:p.Thr670Ile

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

NC_000004.11:g.55595519C>T

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

ENST00000288135.5:c.2009C>T

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1267

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29938766&oldid=2014806052"